LMAT icon

LeMaitre Vascular

84.61 USD
+0.71
0.85%
Updated Apr 1, 3:01 PM EDT
1 day
0.85%
5 days
-0.46%
1 month
-8.19%
3 months
-7.50%
6 months
-6.88%
Year to date
-7.50%
1 year
28.22%
5 years
259.74%
10 years
923.10%
 

About: LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems. LeMaitre generates the majority of its revenue in the United States.

Employees: 630

0
Funds holding %
of 7,398 funds
0
Analysts bullish %
of 3 analysts

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

75% more first-time investments, than exits

New positions opened: 42 | Existing positions closed: 24

24% more call options, than puts

Call options by funds: $332K | Put options by funds: $267K

23% more repeat investments, than reductions

Existing positions increased: 119 | Existing positions reduced: 97

5% more funds holding

Funds holding: 288 [Q3] → 303 (+15) [Q4]

0.81% more ownership

Funds ownership: 93.37% [Q3] → 94.17% (+0.81%) [Q4]

0% more capital invested

Capital invested by funds: $1.95B [Q3] → $1.95B (+$2.12M) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 4 [Q3] → 4 (+0) [Q4]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$95
12%
upside
Avg. target
$105
24%
upside
High target
$110
30%
upside

3 analyst ratings

positive
67%
neutral
33%
negative
0%
Lake Street
Brooks O'Neil
27% 1-year accuracy
4 / 15 met price target
30%upside
$110
Buy
Maintained
28 Feb 2025
Citizens Capital Markets
Daniel Stauder
10% 1-year accuracy
1 / 10 met price target
30%upside
$110
Buy
Maintained
28 Feb 2025
Wells Fargo
Nathan Treybeck
25% 1-year accuracy
1 / 4 met price target
12%upside
$95
Equal-Weight
Initiated
13 Feb 2025

Financial journalist opinion

Based on 9 articles about LMAT published over the past 30 days

Negative
Seeking Alpha
3 days ago
Stocks Falling On Earnings - What To Do? February Dividend Income Report
Alimentation Couche-Tard has several growth vectors in place with a clear 5-year plan, including organic growth and growth by acquisition. Starting in March, I will increase my Smith Manoeuvre contribution from $500 to $750 monthly. CCL Industries reported another good quarter with revenue up 9% and EPS up 5%.
Stocks Falling On Earnings - What To Do? February Dividend Income Report
Positive
Zacks Investment Research
1 week ago
3 Reasons Growth Investors Will Love LeMaitre (LMAT)
LeMaitre (LMAT) could produce exceptional returns because of its solid growth attributes.
3 Reasons Growth Investors Will Love LeMaitre (LMAT)
Neutral
GlobeNewsWire
1 week ago
Precision Optics Appoints Joseph P. Pellegrino, Jr. to Board of Directors
GARDNER, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, is pleased to announce the appointment of Joseph P.
Precision Optics Appoints Joseph P. Pellegrino, Jr. to Board of Directors
Positive
Zacks Investment Research
3 weeks ago
3 Best Earnings Growth Stocks to Buy in March: CAKE, LMAT, HURN
The Cheesecake Factory, LeMaitre Vascular and Huron Consulting Group are currently displaying superb earnings growth.
3 Best Earnings Growth Stocks to Buy in March: CAKE, LMAT, HURN
Neutral
Seeking Alpha
4 weeks ago
When Do You Sell A Winner? - January Dividend Income Report
BlackRock is an interesting case study as I sold it for a nice profit even though the company's investment thesis is still intact. However, some metrics aren't as strong as before. I have a Telus position in one of my other portfolios. I've actively monitored its cash flow metrics. Brookfield Renewable reported another solid quarter with FFO per unit up 21%. The company's hydroelectric, wind, solar, and distributed energy businesses all contributed positively despite weaker North American hydrology affecting hydroelectric generation.
When Do You Sell A Winner? - January Dividend Income Report
Positive
Zacks Investment Research
4 weeks ago
Best Momentum Stocks to Buy for March 4th
OPCH and LMAT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 4, 2025.
Best Momentum Stocks to Buy for March 4th
Positive
Zacks Investment Research
4 weeks ago
New Strong Buy Stocks for March 4th
OPCH, LMAT, C, FFIN and IBCP have been added to the Zacks Rank #1 (Strong Buy) List on March 4, 2025.
New Strong Buy Stocks for March 4th
Neutral
GlobeNewsWire
4 weeks ago
LeMaitre to Participate at Upcoming Investor Conferences in March
BURLINGTON, Mass., March 03, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will be participating in three upcoming investor conferences in March.
LeMaitre to Participate at Upcoming Investor Conferences in March
Positive
Zacks Investment Research
4 weeks ago
LeMaitre (LMAT) Upgraded to Buy: Here's What You Should Know
LeMaitre (LMAT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
LeMaitre (LMAT) Upgraded to Buy: Here's What You Should Know
Neutral
Seeking Alpha
1 month ago
LeMaitre Vascular, Inc. (LMAT) Q4 2024 Earnings Call Transcript
LeMaitre Vascular, Inc. (NASDAQ:LMAT ) Q4 2024 Earnings Conference Call February 27, 2025 5:00 PM ET Company Participants J.J. Pellegrino - Chief Financial Officer George LeMaitre - Chief Executive Officer Dave Roberts - President Conference Call Participants Nathan Treybeck - Wells Fargo Danny Stauder - Citizens JMP Matthew Park - Cantor Fitzgerald Frank Takkinen - Lake Street Capital Markets Michael Petusky - Barrington Research Jim Sidoti - Sidoti & Company Operator Welcome to the LeMaitre Vascular Q4 2024 Financial Results Conference Call.
LeMaitre Vascular, Inc. (LMAT) Q4 2024 Earnings Call Transcript
Charts implemented using Lightweight Charts™